Trials / Completed
CompletedNCT01085318
Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial
A Twenty-four Week, Two Arm, Pilot Trial to Evaluate Remyelination/ Demyelination, Gray Matter Volume and Iron Deposition in the Central Nervous System (CNS) and Immune Status of Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) Treated With Rebif® 44 mcg Subcutaneously (sc) Three Times a Week (Tiw) Compared to a Healthy Control Group
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- EMD Serono · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this trial is to evaluate the effects of Rebif® 44 mcg subcutaneous (sc) three times a week (tiw) on a) remyelination/demyelination, b) lesion and brain volume, c) central nervous system (CNS) iron deposition, and d) immune status in subjects with relapsing-remitting multiple sclerosis (RRMS) RRMS via several MRI techniques.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rebif | 44 mcg tiw |
Timeline
- Start date
- 2010-06-30
- Primary completion
- 2012-02-29
- Completion
- 2012-03-31
- First posted
- 2010-03-11
- Last updated
- 2018-02-23
- Results posted
- 2013-05-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01085318. Inclusion in this directory is not an endorsement.